In this context, although immunotherapy for NSCLC resectable cases has been approved by the Food and Drug Administration (FDA) for both AT and NAT [47,48], AT has not always been linked to significant outcomes [20,28]. This evidence concerns the gene BRD2 and non-small cell lung carcinoma.